Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



The Fertility Show





US Undiagnosed Diseases Program identifies new genetic condition

07 February 2011

By Rosemary Paxman

Appeared in BioNews 594

The genetic basis for a previously unexplained medical condition which causes a painful hardening of the arteries has been identified by the US Undiagnosed Diseases Program (UDP).

Known simply as 'artery-calcification', the rare condition involves a calcium build-up in arteries below the waist and in the joints of patient's hands and feet. It has been observed in only nine individuals from three unrelated families.

Researchers analysed the DNA of nine individuals affected by the disorder and identified a mutation in the NT5E gene. The gene is for enzyme CD73 known to convert adenosine monophosphate (AMP) to adenosine, a molecule believed to inhibit the calcification process. A loss of CD73 can lead to a build-up of AMP resulting in a hardening of the arteries.

Despite the disorder sharing common symptoms with rheumatoid arthritis, the researchers stress that it is a wholly new disorder.

The findings could offer an avenue for treatment although the significance of the findings may not be known for a number of years, said UDP director Dr William Gahl. Experiments normalised CD73 and alkaline phosphate activity in the patients' cells. Alongside this, adenosine treatment also reduced the alkaline phosphate concentration and calcification.

'The role of adenosine was not known before', explained Dr Gahl.

Researchers hope the results could help advance treatments of more common diseases with similar symptoms, for example atherosclerosis, in which arteries hardened and become clogged.

The US National Institute of Health (NIH) established the UDP in 2008 as part of an initiative jointly led by the National Human Genome Research Institute (NHGRI), the NIH Clinical Centre and the NIH Office of Rare Diseases Research.

The findings were published in the New England Journal of Medicine.

 

SOURCES & REFERENCES
National Human Genome Research Institute | 01 February 2011
 
New England Journal of Medicine (NEJM) | 03 February 2011
 
US National Institutes of Health (NIH) | 02 February 2011
 
New Scientist | 02 February 2011
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

23 November 2009 - by Ben Jones 
The US Genetic Information Non-Discrimination Act 2008 (GINA) has come into force introducing new protection against discrimination on the basis of genetic predisposition to disease. The act, signed into law in March of last year by President Bush, outlaws the usage of 'genetic information' to discriminate in the provision of health insurance and prohibits the usage of such information in the making of employment-related decisions such as hiring, firing or promoting.... [Read More]
19 July 2009 - by Sarah Guy 
A venture-backed US start-up company ‘Pathway Genomics' announced its launch last week, and is promising to provide the most comprehensive DNA analysis publicly available; for the lowest price.... [Read More]
17 July 2007 - by Dr Jess Buxton 
Most babies born in the US are now screened for 29 medical conditions, including sickle cell anaemia, cystic fibrosis and hearing loss, according to a new report by the March of Dimes. Two years ago, the charity revealed that only 38 per cent of infants underwent... [Read More]
15 July 2005 - by BioNews 
Most newborn babies in the US are not covered by the full panel of tests recommended by genetic screening experts, according to a report by the March of Dimes charity. Every state requires that infants are tested for a range of conditions, including genetic disorders and hearing problems. However, according... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
PET CONFERENCE
COMMERCIALISATION OF LIFE


Lord Robert Winston, Professor of Science and Society at Imperial College London and speaker at the Progress Educational Trust's conference 'The Commercialisation of Life', taking place in central London on Tuesday 2 December

London, 2 December
Click HERE for details

FREE EVENT
GENETIC CONDITIONS


'Genetic Conditions: How Should Your DNA Be Used in the 100,000 Genomes Project?', a FREE public event being organised by the Progress Educational Trust in central London on the evening of Thursday 6 November 2014

London, 6 November
Click HERE for details

Good Fundraising Code

Advertise your products and services HERE - click for further details